Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C]AZD4144 in Healthy Male Participants
NCT07518459Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD4144 (2 arms), sponsored by AstraZeneca. Primary endpoints: Amount of AZD4144 excreted up to 216 hours, Amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered up to 216 hours and 4 more. Started Feb 2026; status: completed.
02
Drugs
AZD4144
Beyond the preview
Go deeper on NCT07518459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518459.